Marks Group Wealth Management Inc Buys 1,623 Shares of Stryker Co. (NYSE:SYK)

Marks Group Wealth Management Inc lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,936 shares of the medical technology company's stock after acquiring an additional 1,623 shares during the quarter. Stryker comprises approximately 1.8% of Marks Group Wealth Management Inc's holdings, making the stock its 3rd biggest holding. Marks Group Wealth Management Inc's holdings in Stryker were worth $19,124,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Geneva Partners LLC acquired a new position in shares of Stryker during the 3rd quarter valued at $1,435,000. Sentry Investment Management LLC lifted its holdings in shares of Stryker by 9.1% during the 3rd quarter. Sentry Investment Management LLC now owns 1,605 shares of the medical technology company's stock valued at $580,000 after acquiring an additional 134 shares in the last quarter. Greenwood Capital Associates LLC lifted its holdings in shares of Stryker by 2.3% during the 3rd quarter. Greenwood Capital Associates LLC now owns 22,964 shares of the medical technology company's stock valued at $8,296,000 after acquiring an additional 519 shares in the last quarter. FSM Wealth Advisors LLC lifted its holdings in Stryker by 2.8% in the 3rd quarter. FSM Wealth Advisors LLC now owns 1,888 shares of the medical technology company's stock worth $682,000 after buying an additional 52 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in Stryker in the 3rd quarter worth $1,133,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Performance

NYSE SYK traded down $0.84 on Wednesday, hitting $369.02. The stock had a trading volume of 1,364,590 shares, compared to its average volume of 1,257,470. The company's 50-day moving average is $360.91 and its two-hundred day moving average is $345.12. The stock has a market cap of $140.68 billion, a price-to-earnings ratio of 39.55, a P/E/G ratio of 2.77 and a beta of 0.91. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a one year low of $266.93 and a one year high of $376.04.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. During the same period last year, the firm earned $2.46 EPS. The firm's revenue was up 11.9% compared to the same quarter last year. On average, analysts expect that Stryker Co. will post 12.06 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the company's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the business's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,068 shares of company stock valued at $3,693,972. Company insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on shares of Stryker from $345.00 to $350.00 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Barclays boosted their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Piper Sandler reiterated an "overweight" rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Finally, Stifel Nicolaus cut their target price on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average target price of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.